MHE Staff

Marstacimab is being reviewed to prevent or reduce the frequency of bleeding episodes in people with hemophilia A or B. The FDA has set an action date in the first quarter of 2024.

Joe Kvedar, M.D., the immediate past chair of the association, is chairing the 35-member group that will be focused on eliminating barriers to telehealth and other types of virtual health.

In response to the high demand for healthcare professionals and over 2 million annual job openings — a 40% growth rate surpassing the average for all other occupations—healthcare organizations are seeking technological solutions to address this pressing issue.

If approved, elafibranor would be a second-line treatment for patients with primary biliary cholangitis. The Prescription Drug User Fee Act action date is June 10, 2024.

Acoramidis is an oral small molecule to treat patients with transthyretin amyloid cardiomyopathy.

Pharmacy benefit managers have been under pressure to simplify their complicated, obscure pricing tactics.

The survey highlights a growing willingness among employees to pay for premium lens options and a focus on early diagnosis of eye conditions, aligning with the broader trend of holistic well-being.

Cigna has been looking to sell its Medicare Advantage business, perhaps as a way to fend off antitrust objection to the deal.

CTTP is rare hereditary blood clotting disorder stemming from a disease-causing mutation in the ADAMTS13 gene. This gene plays a crucial role in producing the ADAMTS13 enzyme, responsible for regulating blood clotting.

Although the CDC predicted a decline in basic Medicare Part D premiums for 2024 due to the IRA, a recent report revealed an increase in premiums for Medicare Part D prescription drug plans in California, Florida, New York, Pennsylvania and Texas.

After two years of use, the twice-yearly Sunlenca remains active against HIV in patients with multi-drug resistant disease.

Topline results from week 16 of a phase 3b trial demonstrated the efficacy and safety of Tremfya across all skin tones.

Velsipity is the second S1P receptor modulator approved by the FDA to treat patients with moderate-to-severe ulcerative colitis. The wholesale acquisition cost is $6,164 for a 30-day supply.

The FDA is currently reviewing a supplemental biologics license application for Vabysmo in patients with macular edema due to retinal vein occlusion. A decision from the FDA is expected in late 2023.

The IV formulation, a monthly 30-minute, weight-based dosing option, has a wholesale acquisition cost of $2,115 per vial. It will be available in the fourth quarter.

The dosage of Zoryve for children 6 to 11 is the same as for those over the age of 12. The list price is same for both pediatrics and adults — $825 per tube.

In a confirmatory trial, Exkivity did not meet the primary endpoint in treating patients with non-small cell lung cancer with EGFR exon 20 mutations. It will remain available while Takeda works with the FDA on withdrawal timing.

Ryzumi is expected to be available in the first half of 2024. Pricing will be available around the time of launch.

Iyuzeh is a preservative-free latanoprost product that can be stored at room temperature. It has a list price of $299 for a month’s supply.

By offering pre-conception, pregnancy, postpartum, and newborn interventions, as well as primary, wellness, and preventive care, this mobile health center is set to close the access gaps that have long affected the well-being of women and children in Texas.

Early results are expected late next year from the phase 1 trial, which is being funded by the National Institute of Allergy and Infecious Diseases, the Bill & Melinda Gates Foundation and Vir Biotechnology, a San Franciso biotech company focused on vaccines and infectious disease.

The FDA has granted priority review and assigned a Prescription Drug User Fee Act date of March 14, 2024, for resmetirom to treat adult patients with nonalcoholic steatohepatitis (NASH) who have liver fibrosis.

This average rate decrease will lower total premiums by an estimated $130 million.

The keynote speaker for the three-day meeting in Orlando is Sampson Davis, M.D., an emergency medicine physician in New Jersey, an inspirational speaker and co-author of three best-selling books.

The submissions to both the FDA and the EMA are supported by two phase 3 trials demonstrating Skyrizi achieved the primary endpoint of clinical remission.

Sandoz’s Tyruko, the first biosimilar to Biogen’s Tysabri, is expected to be available as soon as possible. Pricing has not yet been made available.

Izervay, which is administered with an intravitreal injection, is expected to be available within the two to four weeks.

Xdemvy is the first treatment that directly targets the mites involved in Demodex blepharitis. It is expected to be available by the end of August 2023 and will have a list price of $1,850 per prescription.

Ycanth is the first drug to treat children and adults with molluscum contagiosum, a viral skin infection. It will be available in September, but pricing information has not yet been released.